Project Grant W81XWH1910728

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $555,774.00 to the University of Alabama at Birmingham (UAB) over a 5-year period starting November 19, 2024. The award supports research to investigate the role of the aryl hydrocarbon receptor (AhR) pathway in regulating the development of T-bet+ B cells, which are implicated in the pathogenesis of systemic lupus...

This federal Project Grant award for $3,364,935.00, provided by the National Institute of Allergy and Infectious Diseases (NIAID) through the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to functionally and mechanistically characterize genetic factors that contribute to the development of systemic lupus erythematosus (SLE). The research aims to elucidate the role of autophagy, a cellular process, in the pathogenesis of SLE, particularly in immune cells and...

This federal Project Grant award in the amount of $700,000.00, provided by the National Institute of General Medical Sciences (CFDA 93.859 - Biomedical Research and Research Training program), supports research to investigate the role of the ARID3A protein in systemic lupus erythematosus (SLE) and other autoimmune diseases. The award will fund a research project at the University of Oklahoma Health Sciences Center to: 1) define genes and epigenetic regions directly regulated by ARID3A expression...

This Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) through the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), supports research to investigate the cellular and molecular mechanisms by which a specific genetic variant of the IFIH1 gene (IFIH1R) promotes the development of systemic lupus erythematosus (SLE). The $2,430,679 award, with a performance period from September 2025 to August 2029, will be used by the...

This $256,808 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to better define the molecular mechanisms that cause and perpetuate systemic lupus erythematosus (SLE). The University of Washington is conducting this research, which focuses on analyzing altered mRNA splicing in SLE neutrophils and exploring the consequences of these splicing changes, including...

This Project Grant award for $300,000 from the Department of Health and Human Services' National Institutes of Health (CFDA 93.310 Trans-NIH Research Support) to Brigham & Women's Hospital Inc. (a subsidiary of Partners Healthcare System) supports research on the role of activated neutrophils and T cells in the pathogenesis of systemic lupus erythematosus (SLE), lupus nephritis, and vasculitis. The research aims to investigate how immune cell abnormalities, specifically the generation of...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to determine the therapeutic potential of CpG-B oligonucleotides (ODNs) for the management of systemic lupus erythematosus (SLE). The $132,930 award, active from January 2025 to July 2028, will support in vitro and in vivo studies using MRL/lpr and humanized mouse models to investigate how CpG-B ODNs, which mimic bacterial...

This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $709,019 to the Benaroya Research Institute at Virginia Mason in Seattle, WA to conduct research on the role of the FOXP3 isoform in regulating autoantibody production and the development of systemic lupus erythematosus (SLE). The key objectives are to: 1) determine how the FOXP3 exon 2 isoform impacts germinal...

This $558,045 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research at Beth Israel Deaconess Medical Center, Inc. (Bidmc) to investigate how the enzyme protein phosphatase 2A (PP2A) controls the function of T cells and contributes to the development of systemic lupus erythematosus (SLE). The research aims to determine how PP2A regulates metabolic enzymes involved in...

This Project Grant award of $423,500 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to develop novel antibodies that target autoreactive B cells as a potential therapeutic approach for treating systemic lupus erythematosus (SLE) patients, particularly among the African American population. The key objectives are to determine the autoantigen specificity and clinical relevance of...